Back to resultsTreatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Primary Purpose
Photodynamic Therapy, Basal Cell Carcinomas
Status
Unknown status
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
Daylight mediated photodynamic therapy
Sponsored by
About this trial
This is an interventional trial for Photodynamic Therapy
Eligibility Criteria
Inclusion Criteria:
- superficial BCC
Exclusion Criteria:
- Immunosuppression
Sites / Locations
- Bispebjerg HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Daylight-PDT
Arm Description
Outcomes
Primary Outcome Measures
complete disappearance of the BCC
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01349361
Brief Title
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Official Title
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Unknown status
Study Start Date
March 2011 (undefined)
Primary Completion Date
January 2013 (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Bispebjerg Hospital
4. Oversight
5. Study Description
Brief Summary
Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Photodynamic Therapy, Basal Cell Carcinomas
7. Study Design
Study Phase
Phase 2
8. Arms, Groups, and Interventions
Arm Title
Daylight-PDT
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Daylight mediated photodynamic therapy
Primary Outcome Measure Information:
Title
complete disappearance of the BCC
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria:
superficial BCC
Exclusion Criteria:
Immunosuppression
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stine R Wiegell, MD, PhD
Email
swie0001@bbh.regionh.dk
Facility Information:
Facility Name
Bispebjerg Hospital
City
Copenhagen NV
ZIP/Postal Code
2400
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stine R Wiegell, MD, PhD
Email
swie0001@bbh.regionh.dk
First Name & Middle Initial & Last Name & Degree
Stine R Wiegell, MD, PhD
12. IPD Sharing Statement
Learn more about this trial
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
We'll reach out to this number within 24 hrs